The first-generation H1 antagonist eliminates the effects of histamine that develop via this receptor type. The central nervous system (CNS) action is caused by blocking brain H3 histamine receptors and inhibiting central cholinergic structures.
Anaphylactic shock, urticaria, allergic rhinitis, serum sickness, haemorrhagic vasculitis (capillary toxicosis), polymorphic exudative erythema, angioedema, itchy dermatoses, pruritis, allergic conjunctivitis and allergic eye diseases, allergic reactions to medicines, chorea, Ménière's disease; postoperative vomiting.
The drug is prescribed in adults by intramuscular injection and as an intravenous drip infusion.
The drug should not be administered subcutaneously due to irritant action.
For intramuscular administration, the single dose is 10-50 mg (1-5 ml); the maximum single dose is 50 mg (5 ml), the maximum daily dose is 150 mg (15 ml). The drug is administered as an intravenous drip at a dose of 20-50 mg (2-5 ml) of Dimedrol in 100 ml of 0.9% sodium chloride solution. The duration of treatment depends on the effect achieved and the tolerability of the drug.
Not for use in paediatric practice.